Chimeric antigen receptor (CAR) T-cell therapy is a next generation therapy which currently treats patients with certain haematological cancers including acute lymphoblastic leukaemia (ALL), adult and acute diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and mantle cell lymphoma (MCL). CAR-T treatment involves the removal and genetic modification of T-cells, which are the body’s immune cells that normally target and kill pathogen-infected cells and other abnormal cells.